Drug Development

With a strategic investment from Persephoni, SelSym Biotech is advancing SymClot, a synthetic blood-clotting agent that could redefine emergency medicine.

Slate Medicines appoints Mark W. Hahn, a CFO known for steering biotechs to massive acquisitions, signaling a major strategic push for its next-gen therapy.

As Corrixr's novel CRISPR therapy nears human trials, the appointment of Seagen veteran Nancy Whiting signals a strategic shift from lab to market.

With a $2M NIH grant, a San Diego biotech is using AI to find the 'on switches' in our DNA, a breakthrough that could make future therapies more potent.

With the hire of COO Ainslie Little, Flagship-backed ProFound Therapeutics signals a strategic shift from pure discovery to operational scale-up.

HERVolution Therapeutics reveals a stunning link between dormant viruses in our genome and metabolic disease, opening a new frontier beyond oncology.

A new bispecific antibody from Kelun-Biotech and Harbour BioMed just got a green light in China, promising quarterly doses for asthma. Is this the innovation that finally unseats the market giants?

Ascletis Pharma announces a new once-daily oral obesity drug, aiming to match the power of injectables like Zepbound in a convenient pill form.

RNAi pioneer Alnylam unveils promising data for its gene-silencing drugs, targeting Alzheimer's and CAA at their genetic source and offering new hope.

Genentech's Gazyva gains FDA Priority Review for a rare kidney disease with no approved treatments, signaling a potential paradigm shift for patients.

A Utah biotech claims its mRNA can disguise cancer as a common virus, harnessing global immunity. We decode the signal: is this a breakthrough or a long shot?

Revel's new enzyme reverses a hallmark of aging. This isn't just a lab success; it's a strategic move challenging the very definition of 'irreversible'.

The U.S. Fish and Wildlife Service again denied a petition to list long-tailed macaques as endangered, a move hailed by researchers but decried by activists.

Seattle's Sound Pharma completes key Phase 3 enrollment for SPI-1005, putting the first-ever approved drug for debilitating Meniere's disease on the horizon.

A small biotech is raising millions with a high-risk funding plan to launch a BOTOX alternative. Can it survive long enough to disrupt a pharma titan?

Ironwood Pharmaceuticals appoints a veteran CMO and launches a key Phase 3 trial, signaling a strategic pivot beyond its blockbuster to conquer rare diseases.

Kura Oncology's upcoming kidney cancer data is just the tip of the iceberg. A closer look reveals a strategic play to make darlifarnib a universal partner drug.

A U.S.-China partnership is testing a drug that could replace cataract surgery. The ZOC2017217 eye drop aims to reverse vision loss for millions.

With a fresh $150M, Mighty Therapeutics is set to expand its groundbreaking mitochondrial drugs from rare diseases to major conditions like Parkinson's.

Landmark Phase 3 data for HBI-8000 not only offers new hope for melanoma patients but validates a powerful "China-to-global" drug development strategy.